Cargando…
Comparing Prospective Incident Severe Acute Respiratory Syndrome Coronavirus 2 Infection Rates During Successive Waves of Delta and Omicron in Johannesburg, South Africa
In high-risk individuals in Johannesburg, during the Delta coronavirus disease 2019 wave, 22% (125/561) were positive, with 33% symptomatic (2 hospitalizations; 1 death). During Omicron, 56% (232/411) were infected, with 24% symptomatic (no hospitalizations or deaths). The remarkable speed of infect...
Autores principales: | Sokhela, Simiso, Bosch, Bronwyn, Hill, Andrew, Simmons, Bryony, Woods, Joana, Johnstone, Hilary, Madhi, Shabir, Qavi, Ambar, Ellis, Leah, Akpomiemie, Godspower, Bhaskar, Esther, Levi, Jacob, Falconer, Jonathan, Mirchandani, Manya, Perez Casas, Carmen, Moller, Karlien, Pilkington, Victoria, Pepperrell, Toby, Venter, Willem Daniel Francois |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9757672/ https://www.ncbi.nlm.nih.gov/pubmed/36540387 http://dx.doi.org/10.1093/ofid/ofac587 |
Ejemplares similares
-
Risks of metabolic syndrome in the ADVANCE and NAMSAL trials
por: Tovar Sanchez, Tamara, et al.
Publicado: (2023) -
Randomized clinical trial of nitazoxanide or sofosbuvir/daclatasvir for the prevention of SARS-CoV-2 infection
por: Sokhela, Simiso, et al.
Publicado: (2022) -
CYP2B6 Genotype and Weight Gain Differences Between Dolutegravir and Efavirenz
por: Griesel, Rulan, et al.
Publicado: (2020) -
Efficacy of Approved Versus Unapproved Vaccines for Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Randomized Blinded Clinical Trials
por: Perez Navarro, Andrea, et al.
Publicado: (2022) -
Concentration-Response Relationships of Dolutegravir and Efavirenz with Weight Change After Starting Antiretroviral Therapy
por: Griesel, Rulan, et al.
Publicado: (2022)